FGF22抗体;FGF22 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using P11763(FGF22 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P11763(FGF22 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Fibroblast Growth Factor 22 (FGF22) is a member of the FGF family, which comprises 23 secreted signaling proteins involved in diverse biological processes, including cell proliferation, differentiation, and tissue repair. FGF22 is primarily expressed in the central nervous system and plays a critical role in synaptic formation, maintenance, and plasticity. It interacts with FGF receptors (FGFRs), particularly FGFR2b, and requires heparan sulfate proteoglycans for signal activation. Dysregulation of FGF22 has been implicated in neurological disorders, such as epilepsy, schizophrenia, and Alzheimer’s disease, as well as peripheral nerve regeneration.

FGF22 antibodies are essential tools for studying its expression, localization, and function. These antibodies enable the detection of FGF22 in tissues or cultured cells via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Neutralizing antibodies are used to block FGF22 activity in functional studies, helping elucidate its role in neuronal development and disease mechanisms. Monoclonal antibodies offer high specificity, while polyclonal antibodies may detect multiple epitopes. Recent research highlights FGF22's therapeutic potential, driving the development of antibodies for targeting aberrant signaling in neurological conditions or enhancing nerve repair. However, challenges remain in optimizing antibody specificity and validating cross-reactivity across species. Overall, FGF22 antibodies are pivotal for advancing both basic research and clinical applications in neurobiology and regenerative medicine.